SCHEDULE 14A
(RULE 14a-101)
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant    □    Filed by a Party other than the Registrant    ☒

Check the appropriate box:

☐ Preliminary Proxy Statement
☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐ Definitive Proxy Statement
☒ Definitive Additional Materials
☐ Soliciting Material Pursuant to 240.14a-12

DEPOMED, INC.
(Name of Registrant as Specified In Its Charter)

HORIZON PHARMA PUBLIC LIMITED COMPANY
HORIZON PHARMA, INC.
(Name of Persons(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

☒ No fee required.
☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

☐ Fee paid previously with preliminary materials.

☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
Horizon Pharma plc ("Horizon Pharma") has filed a definitive proxy statement with the Securities and Exchange Commission (the "SEC") and accompanying WHITE and BLUE proxy cards to be used to solicit requests that Depomed, Inc. ("Depomed") call two related special meeting of shareholders.

This Schedule 14A filing consists of the following screenshots of content available at www.HorizonandDepomed.com, a website established by Horizon Pharma that contains information regarding the proposed acquisition of Depomed by Horizon Pharma and Horizon Pharma’s solicitation of requests that Depomed call two related special meetings of shareholders (the "Website").
Horizon Pharma plc announced today that it has established a website to provide Depomed Inc. shareholders with as much information as possible. In making this decision, we considered the compelling 60 per cent premium proposal to combine our two companies through an all-share, tax free transaction of $3.50 per share.

Despite all the benefits that we, and many other Depomed shareholders who have spoken with, believe will result from a combination of our two companies, Depomed's board and management have been unwilling to meaningfully engage with us. It is our firm conviction that the Depomed board's reluctance to review our acquisition proposals and that they are entrenched and out of step with the desires of most current shareholders.

We urge the true owners of Depomed, play a more important role than ever in bringing our two companies together so that the merits of a combination are realized. We urge you to read these materials carefully. Thank you for your attention to this important matter.

Horizon Pharma plc & Depomed By The Numbers

13

120

$360,000,000

- We have reviewed
- Data Reinvestment in
- Primary Link, Iopalen
- and Special Business Units
- 2012 Reinvestment
- Approximately	Approximate adjusted
- on $100 million -
- EBITDA based on $20
- and $400 million
- guidance

$1,000,000,000

- Horizon Pharma plc's current leverage
- is approximately 6.3x current
- enterprise value

Horizon Pharma plc

1064 Fashion Place
Chicago, IL 60611
773-267-5070
info@horizonpharma.com

Depomed Inc.

1001 Ninth Avenue
San Francisco, CA 94109
310-592-0700
info@depomed.com

Press Releases

Horizon Pharma plc Announces Submission for the Special Meetings N.Y. 9/13
Horizon Pharma plc Announces Exchange Offer to Aspire Depomed Common Shares N.Y. 8/9
Horizon Pharma plc Announces Submission to Include Proposed Amendments N.Y. 9/13
Horizon Pharma plc Announces Exchange Offer to Aspire Depomed Common Shares N.Y. 8/31

Media

Horizon Pharma plc - CME Timothy Weber appears on CNBC Network CNBC, 20 July 2015
Depomed Inc. - CME Adam Goldstein appears on CNBC Network CNBC, 10 June 2015

Contact Information

Financial
John Thoreen
Executive Vice President, Finance and Chief Financial Officer
john.thoreen@horizonpharma.com

Investor Relations
Tim Schrader
Senior Director, Investor Relations
tim.schrader@horizonpharma.com

L.A. Media
Gail Marcus
Gail@MarcusPR.com
Gail Marcus PR
800-992-4600

Editorial
Sharon Winger
Editor, Strategic Communications
sharon.winger@depomed.com

Copyright © 2015 Horizon Pharma plc
Through the proposed combination with Depomed, Inc. (“Depomed”), Horizon Pharma plc (“Horizon Pharma” or “we”) is prepared to deliver substantial value to Depomed shareholders—value that far exceeds anything the Depomed board or its management has been able to achieve. At the same time, our proposed transaction would provide ample liquidity for shareholders should they choose to sell their Horizon Pharma plc shares prior to or after the announcement day.

We are confident that the combined company would be significantly larger and more diversified than either company individually and positioned to realize substantial and sustainable future growth. As a Depomed shareholder, we think you would benefit in two key ways from a combination with us:

• First, a substantial premium for your shares—60 percent based on Depomed’s market price of $20.64 at the close of business on July 6, 2015, the last trading day before our first offer to the Depomed board was publicly announced—and

• Each holder of Depomed common shares will have the right to receive 0.45 Horizon Pharma plc ordinary shares for each of their Depomed shares, based on a $33.00 per share offer price for Depomed stock and 15-day volume weighted average price (“VWAP”) of Horizon Pharma plc shares as of August 12th, 2015, of $34.74.

Second, from your prime brokerage ownership of approximately 32 percent in a new Horizon Pharma, the opportunity to share in the short- and long-term upside potential from this compelling combination.

A combination of Horizon Pharma plc and Depomed is strategically, financially and operationally compelling

It is our strong belief, and that of key Depomed shareholders, that Horizon Pharma plc’s offer to combine with Depomed will be value-enhancing, with compelling benefits such as:

• The combined company will immediately achieve enhanced global scale.

• Based on Depomed’s and our current guidance, we project full-year 2015 net sales and adjusted EBITDA of $1.35 billion and $560 million, respectively, generated by more than 7,800 sales representatives and 1,400 branded medicines for the combined entity.

• The combined company is expected to benefit from meaningful scale and operating synergies as well as tremendous cost savings.

• Horizon Pharma’s leading presence in orphan disease, primary care and specialty markets is complementary to Depomed’s specialty products that treat pain and other central nervous system disorders. We believe the proven execution of our commercial organization and our broad platform will drive increased adoption and even stronger performance of the newly acquired Depomed products NUCLON® (Brand name: OXANDROLON) as well as its existing medicines Galvestin®, LAAM,骁悉® and Ziprelix.

• We believe the combination of our companies will provide additional financial flexibility and increased free cash flow for future M&A activity, enhanced access to the capital markets and considerably lower borrowing costs. For illustrative purposes, Horizon Pharma’s current leverage ratio is 6.4x as compared to Depomed’s 5.4x as adjusted EBITDA, under Horizon Pharma’s current offer, we anticipate that Depomed’s 15.75% of senior secured notes having interest at 10.75% would be retired through use of cash on hand and a new debt issuance with an expected interest rate less than one-half Depomed’s current interest cost, allowing the combined company to realize a considerable cost savings and further adding to the value proposition for shareholders.

Yesthough we believe in the value and importance of the proposed offer to shareholders, we have also been listening to the feedback of our board of directors, and management has been working and communicating on a meaningful engagement with Horizon Pharma plc over the past several months. As a result, Horizon Pharma plc now actively soliciting Depomed’s shareholders to join us in the calling of a special meeting of shareholders in connection with Horizon Pharma’s proposal to remove and replace all of the current Depomed’s directors and to approve a series of bylaw amendments recently adopted by the Depomed board aimed to hinder and delay the calling of a special meeting of shareholders. Horizon Pharma plc has also launched an exchange offer, which provides an additional mechanism for shareholders to support the consummation of our proposed combination.

To learn more about Horizon Pharma plc’s compelling offer to acquire Depomed, please read our Special Letter to Depomed Shareholders.

The Exchange Offer & Solicitation for the Special Meeting

Horizon Pharma plc

105 Madison Avenue
New York, NY 10016
www.horizonpharma.com

Call collect (212) 410-3599
Call toll free (800) 513-7265

Investors
John Thomas
Investor Relations
jthomas@horizonpharma.com

U.S. Media
Geoff Carlin
Corporate Communications
geoff@horizonpharma.com

Tom Vierling
Senior Director, Investor Relations
tom.vierling@horizonpharma.com

Investor Media
Ray Gerino
SVP Communications
ray@horizonpharma.com

David Forst
Executive Vice President
The Vierling Group
david@vierlinggroup.com

Copyright © 2015 Horizon Pharma plc.
9/10/15 - Horizon Pharma plc Has Commenced Solicitation of Depomed, Inc. Shareholders for Calling of Special Meetings

9/8/15 - Horizon Pharma plc Commences Exchange Offer to Acquire Depomed Common Shares

8/15/15 - Horizon Pharma plc Amends Solicitation Statement to Include Proposed Nominees

8/15/15 - Horizon Pharma plc Sends Letter to Depomed’s Board

8/3/15 - Horizon Pharma plc Commences Process To Request a Special Meeting

7/21/15 - Horizon Pharma plc Increases Offer for Depomed to $35.00 Per Share

7/13/15 - Horizon Pharma plc Responds to Depomed’s Adoption of a Poison Pill

7/7/15 - Horizon Pharma plc Announces Proposal To Acquire Depomed
Calling for the Special Meetings

Horizon Pharma plc ("Horizon Pharma" or "we"/"it") hereby believes that Depomed, Inc. ("Depomed") shareholders should have the right to consider what they believe is a highly compelling acquisition offer. We believe that engaging in meaningful discussions with Horizon Pharma plc and working to enhance value for Depomed shareholders, the Depomed board of directors and management have the power to spend their time and Depomed resources engaging in what serves as a cesspool of misinformation and distraction.

Based on the Depomed board of directors' rapid enforcement of a deal to consider it unnecessary for Horizon Pharma plc to own the shareholders to call a meeting, the Depomed board of directors and management have the power to spend their time and Depomed resources engaging in what serves as a cesspool of misinformation and distraction.

Under Depomed's charter and bylaws, shareholders owning 10 percent or more of Depomed's common stock have the right to call a Special Meeting. Horizon Pharma, which currently owns approximately 9.5 percent of Depomed's common shares, intends to solicit other shareholders to join in the calling of such Special Meetings.

Would Horizon Pharma plc make a $17.50 per share cash offer for Depomed shares from shareholders owning, together with Horizon Pharma plc, at least 15 percent of Depomed common stock, Horizon Pharma plc will announce its call to call Special Meetings as follows:

1. The first Special Meeting will consider the removal of all current Depomed directors effective upon the acceptance of Depomed's bylaw amendments, and the appointment and election of six independent directors nominated by Horizon Pharma plc.

2. The second Special Meeting will consider the election of new members of the directors. If the current Depomed directors are removed at the first meeting, with the new directors comprising the new independent nominees, we believe that Horizon Pharma plc believes would consider to acquisition offers in an independent manner consistent with their integrity duties under the law.

Once Special Meetings occur, Horizon Pharma plc would provide any materials for voting on such proposals at the Special Meetings, and then solicits and receives proxies and votes on its proposals. At the Special Meetings, Depomed shareholders would be permitted to vote in favor of all, any or none of Horizon Pharma plc's proposals.

Horizon Pharma plc urges all Depomed shareholders to support the solicitation and, accordingly, to take part in the Special Meetings. Although there can be no assurance that the consent of our proposals at the Special Meetings will result in the Depomed board of directors and management engaging with us in a meaningful dialogue regarding a combination, we believe that all of the current Depomed directors and management would, if elected, place the interests of the shareholders in a Special Meeting, and engage in good faith discussions with us, in contrast to the current management's lack of communications.

Your support of our combination solicitation to call the special meetings is extremely important. Our current acquisition offer is in line with these objectives and in the Special Meetings process with submitting our proposals to use of Depomed shareholders. You, the true owner of Depomed, can play an important role in shaping our two companies together in a way that benefits management our stockholders.

LIFT YOUR VOTE HEARD

Support the calling of the Special Meetings by completing, signing and dating the WHITE and BLUE proxy cards accompanying the solicitation materials, and by returning the cards in the enclosed envelope as promptly as possible to Mackenzie Partners, Inc., the registrar and transfer agent for Depomed, in order to have your vote counted. If you have any questions about completing, executing and dating your WHITE and BLUE proxy cards, or delivering the document to Mackenzie Partners, Inc., or otherwise require assistance, please contact:

Mackenzie Partners, Inc.
1350 Market Street
Philadelphia, PA 19107
www.mackenziepartners.com
Toll-free: 877-261-5037

The Exchange Office
1417 Corporate Place
Burlington, NC 27215
Toll-free: 877-380-3770
www.valueaddexchange.com

The Exchange Office
1417 Corporate Place
Burlington, NC 27215
Toll-free: 877-380-3770
www.valueaddexchange.com

For questions, please contact:
John W. Slaven
Mackenzie Partners, Inc.
547 West 7th Street, Suite 1700
Minneapolis, MN 55402
Email: john.w.slaven@mackenziepartners.com
Phone: (612) 330-4800
Fax: (612) 330-4888

Don't Miss Out
Make sure you vote for the Special Meetings.

Mackenzie Partners, Inc.
1350 Market Street
Philadelphia, PA 19107
www.mackenziepartners.com

For questions, please contact:
John W. Slaven
Mackenzie Partners, Inc.
547 West 7th Street, Suite 1700
Minneapolis, MN 55402
Email: john.w.slaven@mackenziepartners.com
Phone: (612) 330-4800
Fax: (612) 330-4888

Copyright 2016 Horizon Pharma plc
About the Exchange Offer

Horizon Pharma plc ("Horizon Pharma" or "we") is committed to effecting what it believes to be a strategically, financially and operationally compelling combination with Depomed, Inc. ("Depomed"). To that end, on September 8, 2015, Horizon Pharma plc commenced an exchange offer for all of the outstanding common shares of Depomed (the "Exchange Offer"). The Exchange Offer demonstrates Horizon Pharma's resolve to commit to a transaction with Depomed and provides an additional mechanism for shareholder empowerment.

- Under the terms of the Exchange Offer, tendering Depomed shareholders would be able to exchange each share of Depomed common stock for 0.91 Horizon Pharma plc ordinary shares, based on a $33.06 per share offer price for Depomed stock and 15 day volume weighted average price (VWAP) of Horizon Pharma plc as of August 17th, 2015 of $36.74.
- Horizon Pharma's offer to Depomed shareholders represents a 60 percent premium based on Depomed's unaudited closing share price of $20.54 as of July 6, 2015, the final trading day prior to Horizon Pharma's first public offer to acquire Depomed.
- 54 percent premium to Depomed's 36-day VWAP of $21.81 on July 6, 2015.
- Depomed shareholders would have a pro forma ownership of approximately 32 percent of the combined company based on Horizon Pharma's estimates and assumptions.

Horizon Pharma plc is very proud of the progress that it has made in executing on its highly successful growth strategy. Within the past two years, Horizon Pharma plc has successfully completed and integrated four acquisitions, enabling Horizon Pharma plc to rapidly grow its sales and adjusted EBITDA, as well as significantly deepen and diversify its core business platforms. Notably, each of Horizon Pharma's acquisitions has been immediately and substantially accretive to the benefit of our shareholders.

We firmly believe that the current offer to acquire Depomed is consummated, you will be very pleased to become an owner of this new Horizon Pharma. We are confident that the combined company would be significantly larger and more diversified than either company individually. Moreover, in our view, the combined company would be uniquely positioned to realize significant and sustainable revenue and earnings growth and strong cash flows, as well as be able to generate short and long-term value for our respective shareholders.

We strongly encourage you to tender your shares in order to realize the many benefits of a combination.

Shareholder questions regarding the Exchange offer or requests for offering documents should be directed to Horizon Pharma's information agent for the exchange offer:

Mackenzie Partners, Inc.
105 Madison Avenue
New York, NY 10016
Email: request@mackenziepartners.com
Call collect: (212) 529-1090
Call toll-free: (800) 322-2805

The Exchange Offer will expire at 5 p.m., Eastern Time on November 6, 2015, but may be extended by Horizon Pharma. The offering documents, including a preliminary prospectus/offer to exchange and a related letter of offer and transmittal, describing the Exchange Offer and the process for Depomed shareholders to tender Depomed common shares into the Exchange Offer, will be delivered to Depomed shareholders.

Investors
John Thomas
Executive Vice President, Strategy and Investor Relations
investor.relations@horizonpharma.com

Tina Vetter
Vice President, Investor Relations
investor.relations@horizonpharma.com

U.S. Media
Geoff Curns
Group Vice President, Corporate Communications
geoff.curns@horizonpharma.com

foreign Media
Rebecca White
gan@girome.com
Consen on Horizon Pharma plc:

"Viewing the proposed Depomed transaction within that broader context of Horizon’s evolution, we believe this transaction makes exceedingly good strategic sense, is nicely value creating, and provides enhanced and durable diversification.”

ABC on Depomed, Inc.:

"Per our earlier note, we believe the asset is worth more in the hands of Horizon given the greater $484 million in revenues Horizon could provide, cost savings opportunity, ability to refinance the 13.75% debt and expected reduction of the tax burden.”

Leerink on Depomed, Inc.:

“Perception that this deal may not generate an adequate amount of synergies to be attractive does not make sense to us. If we looked through Horizon’s past deal transaction history, none was built on cost cutting - rather all were based on generating revenue upside from increased promotion and better pharmacy pull through. We see the Depomed deal as being no different.”

Stifel on Horizon Pharma plc:

“We continue to view a HDPN-DEPO combination as attractive, and believe HDPN has made a strong case to DEPO shareholders.”

Guggenheim on Horizon Pharma plc:

“The debate whether Depomed was paid for Nasmyth is yet to be determined, but we believe this is a growth product and the numbers work better within Horizon with the significant tax advantages.”
9/8/19 - Horizon pushes hostile $2.4 billion bid for drugmaker Depomed with start of shareholder offer – Associated Press


7/21/15 - Horizon raises offer for rival drugmaker Depomed – Financial Times

7/10/15 - Horizon Pharma plc CEO Timothy Welbot Appears on CNBC (video) – CNBC

7/7/16 - Ireland's Horizon Pharma launches hostile $3 billion bid for U.S. rival – Fortune

7/7/15 – Depomed Learns It’s Tough to Say No Amid a Deal Frenzy; Real M&A – Bloomberg

7/7/15 – The Tax Inversion Wave Keeps Rolling – The Wall Street Journal

6/16/15 - Horizon Pharma plc CEO Timothy Welbot on CNBC’s Mad Money (video) – CNBC
The Exchange Offer & Solicitation for the Special Meetings
Mackenzie Partners, Inc.
105 Madison Avenue
New York, NY 10016
depotnote@mackenziepartners.com
Call collect (212) 929-5500
Call toll-free (800) 322-2882

Investors
John Thomas
Executive Vice President, Strategy and Investor Relations
investor-relations@horizonpharma.com

Tina Ventura
Vice President, Investor Relations
investor-relations@horizonpharma.com

U.S. Media
Geoff Curtis
Group Vice President, Corporate Communications
media@horizonpharma.com

Ireland Media
Ray Gordon
Gordon MRM
gay@groupmrm.ie

Daniel Younger
Keiser and Company
daniel.younger@keiser.com

Copyright 2015 Horizon Pharma plc
Forward-Looking Statements

Some of the statements on the Website and in the documents contained on the Website may contain forward-looking statements, including, but not limited to, statements related to Horizon Pharma’s offer to exchange its ordinary shares for all issued and outstanding shares of Depomed’s stock and the potential strategic and financial benefits thereof, the future financial performance and prospects of each of Horizon Pharma and Depomed, Horizon Pharma’s business strategy and plans, and other statements that are not historical facts.

These forward-looking statements are based on Horizon Pharma’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks that the conditions to the exchange offer will not be satisfied, Horizon Pharma will ultimately not pursue a transaction with Depomed or Depomed will reject engaging in any transaction with Horizon Pharma; if the conditions of the exchange offer are satisfied and/or a transaction is negotiated between Horizon Pharma and Depomed, risks related to Horizon Pharma’s ability to complete the acquisition on the proposed terms; the possibility that competing offers will be made; risks associated with business combination transactions, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the acquisition will not be realized; risks related to future opportunities and plans for the combined company, including uncertainty of the expected financial performance and results of the combined company following completion of the proposed acquisition; disruption from the proposed acquisition, making it more difficult to conduct business as usual or maintain relationships with customers, employees or suppliers; and the possibility that if the combined company does not achieve the perceived benefits of the proposed acquisition as rapidly or to the extent anticipated by financial analysts or investors, the market price of Horizon Pharma’s shares could decline, as well as other risks related to the Horizon Pharma and Depomed’s businesses, including the ability to grow sales and revenues from existing products; competition, including potential generic competition; the ability to protect intellectual property and defend patents; regulatory obligations and oversight; and those risks detailed from time-to-time under the caption “Risk Factors” and elsewhere in Horizon Pharma’s and Depomed’s respective filings and reports with the SEC. Horizon Pharma undertakes no duty or obligation to update any forward-looking statements contained in this presentation as a result of new information, except as required by applicable law or regulation.
Note Regarding Use of Non-GAAP Financial Measures

Some of the documents contained on the Website may contain certain financial measures such as adjusted EBITDA, or earnings before interest, taxes, depreciation and amortization, pro forma net sales adjusted for sales of certain products pre-acquisition and adjusted net income that include adjustments to GAAP figures. Adjustments to GAAP figures as well as EBITDA exclude acquisition transaction related expenses, loss on debt extinguishment, as well as non-cash items such as share-based compensation, depreciation and amortization, royalty accretion, non-cash interest expense, and other non-cash adjustments. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. In the case of pro forma net sales, the figures exclude net sales of orphan and oncology products and include net sales attributed to other companies that marketed certain products prior to their acquisition by Horizon Pharma or Depomed, as applicable.

Horizon Pharma believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Horizon Pharma’s and Depomed’s financial performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of Horizon Pharma’s operational results, trends and expectations, including in relation to Depomed. In addition, these non-GAAP financial measures are among the indicators Horizon Pharma’s management uses for planning and forecasting purposes and measuring Horizon Pharma’s performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by Horizon Pharma may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Horizon Pharma has not provided a reconciliation of adjusted EBITDA or adjusted net income outlook for future periods to a net income (loss) outlook because certain items that are a component of net income (loss) but not part of adjusted EBITDA and/or adjusted net income, such as the gain (loss) on derivative revaluation associated with convertible senior notes, stock compensation, acquisition related expenses and certain purchase accounting items such as intangibles and step-up inventory, cannot be reasonably projected, either due to the significant impact of changes in Horizon Pharma’s or Depomed’s stock price on share-based compensation, the variability associated with acquisition related expenses due to timing and other factors.
Third Party–Sourced Information

Certain information included in the documents contained on the Website has been sourced from third parties. Horizon Pharma does not make any representations regarding the accuracy, completeness or timeliness of such third party information. Permission to cite such information has neither been sought nor obtained.

All information contained on the Website and in the documents contained on the Website regarding Depomed, including its businesses, operations and financial results, was obtained from public sources. While Horizon Pharma has no knowledge that any such information is inaccurate or incomplete, Horizon Pharma has not had the opportunity to verify any of that information.

Additional Information

Neither the Website nor any of the documents contained on the Website constitute an offer to buy or solicitation of any offer to sell or vote securities and each is for informational purposes only. The Website and the documents contained on the Website relate to the offer commenced by Horizon Pharma to exchange each issued and outstanding share of Depomed common stock for 0.95 Horizon ordinary shares. The offer will be made only through the Tender Offer Statement on Schedule TO or the Prospectus/Offer to Exchange included in the Registration Statement on Form S-4 (including the Letter of Transmittal and related documents and as amended from time to time, the “Exchange Offer Documents”) that Horizon Pharma has filed with the SEC. The Website and the documents contained on the Website also relate to a solicitation by Horizon Pharma of Depomed’s shareholders to call two special shareholders meetings to consider the principal proposals described in the Special Meetings Solicitation Statement (as defined below). On September 8, 2015, Horizon Pharma filed a definitive solicitation statement and accompanying WHITE and BLUE proxy cards with the SEC with respect to the solicitation of proxies to call two related special meetings of shareholders (including any amendments and supplements, the “Special Meetings Solicitation Statement”). Subject to further developments, Horizon Pharma may file one or more supplements to the Special Meetings Solicitation Statement and additional solicitation statements and/or one or more proxy statements or other documents with the SEC in connection with such special shareholders meetings, and Horizon Pharma (and, if a negotiated transaction is agreed upon, Depomed) may file one or more registration statements, prospectuses, proxy statements, Exchange Offer Documents or other documents with the SEC in connection with the offer or any other proposed transaction involving Horizon Pharma and Depomed. INVESTORS AND SECURITY HOLDERS OF HORIZON PHARMA AND DEPOMED ARE URGED TO READ CAREFULLY THE SPECIAL MEETINGS SOLICITATION STATEMENT (INCLUDING ANY SUPPLEMENTS), THE ACCOMPANYING WHITE AND BLUE PROXY CARDS AND OTHER SOLICITATION STATEMENTS, PROXY STATEMENTS AND DOCUMENTS FILED WITH THE SEC IN CONNECTION WITH THE SPECIAL SHAREHOLDERS MEETINGS AND THE EXCHANGE OFFER DOCUMENTS (INCLUDING ANY AMENDMENTS AND SUPPLEMENTS) AND ANY REGISTRATION STATEMENTS, PROSPECTUSES, PROXY STATEMENTS AND OTHER DOCUMENTS FILED WITH THE SEC IN CONNECTION WITH THE OFFER OR ANY OTHER PROPOSED TRANSACTION INVOLVING HORIZON PHARMA AND DEPOMED WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT HORIZON PHARMA, DEPOMED, THE SPECIAL SHAREHOLDERS MEETINGS, THE OFFER OR ANY OTHER PROPOSED TRANSACTION INVOLVING HORIZON PHARMA AND DEPOMED, AS APPLICABLE. Investors and security holders may obtain free copies of the documents filed with the SEC at the SEC’s web site at www.sec.gov or by directing a request to Horizon Pharma’s Investor Relations department at Horizon Pharma, Inc., Attention: Investor Relations, 520 Lake Cook Road, Suite 520, Deerfield, IL 60015 or to Horizon Pharma’s Investor Relations department at 224-383-3400 or by email to investor-relations@horizonpharma.com. Investors and security holders may obtain free copies of the documents filed with the SEC on Horizon Pharma’s website at www.horizonpharma.com under the heading “Investors” and then under the heading “SEC Filings.”
Certain Information Regarding Participants

Horizon Pharma and/or Depomed and their respective directors, executive officers and certain other employees and the Horizon Pharma nominees may be deemed participants in a solicitation of proxies in connection with the requests to call the special shareholders meetings. You can find information about Horizon Pharma’s directors, executive officers and such certain other employees and any individuals Horizon Pharma is seeking to nominate for election to the Depomed board of directors, as described in the Special Meetings Solicitation Statement, in Horizon Pharma’s Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the SEC on February 27, 2015, Horizon Pharma’s definitive proxy statement filed with the SEC on May 6, 2015, Horizon Pharma’s Current Report on Form 8-K/A filed with the SEC on July 27, 2015 and the Special Meetings Solicitation Statement and in such other solicitation statements, proxy statements or other documents that would be filed with the SEC in connection with the special shareholders meetings. You can find information about Depomed’s directors, executive officers and its employees who are participants in such solicitation in Depomed’s definitive proxy statement filed with the SEC on April 16, 2015 and the Special Meetings Solicitation Statement and in such other solicitation statements, proxy statements or other documents that would be filed with the SEC in connection with the special shareholders meetings. These documents are available free of charge at the SEC’s web site at www.sec.gov and, with respect to Horizon Pharma, from Investor Relations at Horizon Pharma as described above. Additional information regarding the interests of such potential participants is included in the Special Meetings Solicitation Statement and will be included in one or more registration statements, proxy statements or other documents filed with the SEC if and when they become available.

The Website is sponsored by Horizon Pharma.